age-related macular degeneration

Roche's Vabysmo shows potential to treat eye disorder common in Asia
Fierce Pharma
Fri, 11/22/24 - 11:19 am
Roche
Vabysmo
age-related macular degeneration
Asia
Ionis axes eye disease from targets of Roche-partnered prospect after data disappoint
Fierce Biotech
Thu, 08/1/24 - 11:50 am
Ionis Pharmaceuticals
Roche
age-related macular degeneration
Astellas’ Izervay reduces GA lesion growth in Phase III trial
Clinical Trials Arena
Mon, 11/6/23 - 09:51 am
Astellas
Izervay
geographic atrophy
age-related macular degeneration
clinical trials
Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Fierce Pharma
Thu, 08/10/23 - 09:49 pm
Regeneron
Eylea
age-related macular degeneration
FDA
Things don't look good for NGM's Merck-partnered eye asset as phase 2 fail sends stock plummeting
Fierce Biotech
Mon, 10/17/22 - 11:17 pm
NCM Biopharmaceuticals
clinical trials
Merck
age-related macular degeneration
Apellis' eye med application on track for next year after FDA OKs inclusion of phase 2 data
Fierce Pharma
Mon, 11/15/21 - 11:51 pm
Apellis Pharmaceuticals
pegcetacoplan
FDA
clinical trials
age-related macular degeneration
Gemini axes CSO and 20% of staff to focus on late-phase plans
Fierce Biotech
Tue, 10/5/21 - 10:43 am
Gemini Therapeutics
layoffs
gene therapy
CSO
age-related macular degeneration
FDA approves first biosimilar to top-selling eye drug Lucentis
BioPharma Dive
Mon, 09/20/21 - 10:55 pm
FDA
biosimilars
Lucentis
age-related macular degeneration
Byooviz
Biogen
Samsung Bioepis
Outlook heads to regulators with eye-friendly Avastin
EP Vantage
Wed, 08/4/21 - 10:53 am
Outlook Therapeutics
Avastin
age-related macular degeneration
FDA
Lucentis
3 Biotech Stocks With Big Catalysts in June
Motley Fool
Tue, 06/22/21 - 10:55 am
Corbus Pharmaceuticals
lenabasum
clinical trials
Gemini Therapeutics
age-related macular degeneration
Intellia Therapeutics
hATTR-pn
Gyroscope bags $148M for AMD gene therapy trials, mulls IPO
Fierce Biotech
Fri, 03/26/21 - 10:53 am
Gyroscope
gene therapy
IPOs
age-related macular degeneration
Genentech Could Regain the Blindness-Related Disease Market with New Treatment
BioSpace
Sat, 02/13/21 - 11:01 pm
Roche
Genentech
clinical trials
faricimab
age-related macular degeneration
nAMD
RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration
Pharmaceutical Business Review
Wed, 03/18/20 - 10:17 am
RIBOMIC
AJU Pharm Co
Korea
RBM-007
age-related macular degeneration
3 Biotech Stocks That Soared Last Week
Motley Fool
Sun, 09/15/19 - 09:51 pm
Acadia Pharmaceuticals
Nuplazid
Mesoblast
Grunenthal
MPC-06-ID
Kodiak Sciences
age-related macular degeneration
Novartis backs brolucizumab with new head-to-head Eylea trial
Pharmaforum
Mon, 09/9/19 - 08:15 pm
Novartis
clinical trials
brolucizumab
Eylea
Bayer
Regeneron
age-related macular degeneration
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
An eye drop for macular degeneration shows promise in animal studies
Fierce Biotech
Fri, 07/20/18 - 09:44 am
age-related macular degeneration
Macregen
Apellis touts new data for eye drug hopeful
Biopharma Dive
Sun, 02/25/18 - 11:22 am
Apellis
eye health
APL-2
age-related macular degeneration
LumiThera wins Health Canada nod for photobiomodulation trial
Mass Device
Fri, 03/25/16 - 09:36 am
LumiThera
Canada
photobiomodulation
devices
age-related macular degeneration
The Next Blockbusters Could Be Balms For Aging Eyes
Investors.com
Thu, 09/3/15 - 09:10 am
age-related macular degeneration
Bayer
Regeneron
Ophthotech
Allergan
Novartis
Applied Genetic Technologies
Avalanche Biotechnologies
Roche
Lucentis
Eylea

Pages